Drugs / INL1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03875183 | Jan 2020 → Dec 2022 | heart failure | Innolife Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INL1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03875183 ↗ |